Navigation Links
New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline

RIDGEFIELD, Conn., May 8, 2012 /PRNewswire/ -- Boehringer Ingelheim will present the latest data from its respiratory research pipeline at the Annual International Conference of the American Thoracic Society (ATS 2012), in San Francisco, CA, May 18 - 23. The 14 abstracts include results from a dose-ranging study evaluating tiotropium in subjects with moderate persistent asthma, additional analyses of data from the Phase II TOMORROW trial (To Improve Pulmonary Fibrosis with BIBF 1120), and results from a Phase II trial on the long-acting b2-agonist olodaterol in patients with COPD.

Boehringer Ingelheim's abstracts in respiratory research can be accessed through the ATS website, The Boehringer Ingelheim data will remain under embargo until the date and time that the data are presented (see details below). The ATS International Conference is one of the largest gatherings of pulmonary, critical care and sleep clinicians and researchers in the world, with 13 thousand attendees from 95 countries last year.

Collectively, these data underscore the company's focus on finding answers to the challenges faced by patients living with lung disease.

Title Lead Author Presentation details Dose-Ranging Study Of

Tiotropium As Treatment

For Moderate Persistent

Asthma In Adolescents

C. Vogelberg

Scientific Abstract # 305


Date: Tuesday, May 22

Time: 8:15 a.m. – 10:45 a.m.

PDT / 11:15 a.m. – 1:45 p.m.

EDTBIBF 1120Title Lead Author Presentation details Treatment Of IPF With The

Tyrosine Kinase Inhibitor

BIBF 1120: Patient-

Reported Outcomes


K.K. Brown

Oral Presentation


Date: Monday, May 21

Time: 2:00 p.m – 4:30 p.m.

(data presented at 2:45 p.m.)

PDT / 5:00 p.m. – 7:30 p.m.

(data presented at 5:45 p.m.) EDTEfficacy of the Tyrosine

Kinase Inhibitor BIBF 1120

in Patients with IPF:

Consistent Pattern of

Primary Endpoint Results

in Sensitivity Analyses of

the TOMORROW trial

L. Richeldi

Oral Presentation


Date: Monday, May 21

Time: 2:00 p.m – 4:30 p.m.

(data presented at 2:30 p.m.)

PDT / 5:00 p.m. – 7:30 p.m.

(data presented at 5:30 p.m.) EDTOlodaterolTitleLead Author Presentation details Comparison Of 24-Hour

FEV1 Profile For Once-

Daily Versus Twice-Daily

Treatment With

Olodaterol, A Novel Long-

Acting b2-Agonist, In

Patients With COPD

G. Joos

Thematic Poster # D60


Date: Monday, May 21

Time: 10:45 a.m – 12:30 p.m.

PDT / 1:45 p.m. – 3:30 p.m.

EDTLung FunctionTitleLead Author Presentation details Lung Function And

Exercise Impairment In

Patients With GOLD Stage


D. E. O'Donnell

Thematic Poster  # G74


Date: Wednesday, May 23

Time: 8:15 a.m. – 4:30 p.m.

PDT / 11:15 a.m. – 7:30 p.m. EDT

Poster Discussion from

10:45 a.m. – 12:30 p.m. PDT /

1:45 p.m. – 3:30 p.m. EDTBoehringer Ingelheim: Leading respiratory forwardTreatment of respiratory diseases has been a major area of focus for Boehringer Ingelheim for more than 90 years and significant resources are dedicated to research in this field. In addition to new possible treatment options for COPD, Boehringer Ingelheim has also branched out into developing treatment options for other airway diseases, including asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.

About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit and follow us on Twitter at


SOURCE Boehringer Ingelheim
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... Raton, Florida (PRWEB) , ... November 25, 2015 ... ... diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under ...
Breaking Medicine News(10 mins):